Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 172 Parkinson's papers of 10,497 | 0.32 |
| pathways Reactome | 7 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2592
Sealed predictions
- GPX4 in dopamine neurons, braak-0.02 (p 0.965) → +0.56 (p 0.116)receipt 2599
Swarm cases
receipt 2599: GPX4 in dopamine neurons, braak
- power
- full sample +0.37 (p 0.132, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.30 (p 0.221, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.42 (p 0.080, n 18). could be the mix.
- skeptic
- leave-one-out range +0.28 to +0.48, sign flips 0; without severely affected donors +0.37 (p 0.132, n 18). fragile.
- cell type
- strongest in OPCs: +0.65 (p 0.0036, n 18) vs +0.37 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GPX4 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GPX4 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.25 p 0.374 (needs p < 6.8e-4)
Receipts
loading the receipts